FTH catalyst calendar

Faeth Therapeutics, Inc.

Upcoming catalysts
3
Cash runway
7.5 months
Cash & investments
$27M

Faeth Therapeutics, Inc. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is Next quarterly earnings (projected) on November 3, 2026, a projected date rather than a confirmed one. There are 3 upcoming events on record.

Cash runway is approximately 7.5 months based on the most recent reported cash position and quarterly operating burn as of 2026-06-30.

Upcoming catalysts

DateEventTypePhase
November 3, 2026 est. Next quarterly earnings (projected) Earnings —
September 15, 2028 Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer Trial Milestone Phase 2
May 15, 2029 Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer Trial Milestone Phase 1/Phase 2

Track FTH alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open FTH in the tracker

Recent history

DateEventTypePhase
September 17, 2026 8-K filed: Leadership change Corporate —
August 4, 2026 Quarterly results filed (8-K) Earnings —
July 23, 2026 8-K filed: Leadership change Corporate —
June 18, 2026 8-K filed: Material agreement, Other event Corporate —
June 15, 2026 8-K filed: Leadership change, Reg FD disclosure, Other event Corporate —
June 10, 2026 8-K filed: Leadership change Corporate —
May 22, 2026 8-K filed: Other event Filing —
May 21, 2026 8-K filed: Other event Filing —
May 15, 2026 Quarterly results filed (8-K) Earnings —
April 16, 2026 8-K filed: Leadership change Corporate —
March 30, 2026 Quarterly results filed (8-K) Earnings —
February 18, 2026 8-K filed: Material agreement, Acquisition completed, Leadership change, Reg FD disclosure Corporate —
February 13, 2026 8-K filed: Leadership change Corporate —
December 23, 2025 8-K filed: Leadership change Corporate —
November 14, 2025 Quarterly results filed (8-K) Earnings —
October 30, 2025 8-K filed: Reg FD disclosure Filing —
October 17, 2025 8-K filed: Reg FD disclosure Filing —
August 5, 2025 Quarterly results filed (8-K) Earnings —
July 9, 2025 8-K filed: Listing / standard notice Corporate —
May 6, 2025 Quarterly results filed (8-K) Earnings —
April 30, 2025 Combination of Serabelisib and Insulin Suppressing Diet With or Without Nab-paclitaxel in Subjects With Advanced Solid Tumors With PIK3CA Mutations Trial Milestone Phase 1
January 24, 2023 A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.